Weight loss jabs can cut risk of heart attack or stroke by fifth, study suggests

Novo Nordisk said it expects to file for regulatory approvals of a label indication expansion for Wegovy in the US and the EU in 2023.

Novo Nordisk tested its Wegovy weight loss jab as part of a trial over five years (PA)

Weight loss jabs can reduce the risk of a heart attack or stroke in obese people with cardiovascular disease by a fifth, researchers claim.

Pharmaceutical company Novo Nordisk conducted a five-year study of semaglutide, which is sold as Wegovy.